Migraine prevention treatment that covers your patients for a full 24 hours2

**NEW STARTS**

Dosage and administration for new patients only

**Migraine prevention titration schedule**

<table>
<thead>
<tr>
<th>Total daily dose</th>
<th>Once daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 mg</td>
<td>25 mg</td>
</tr>
<tr>
<td>50 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>75 mg</td>
<td>75 mg</td>
</tr>
<tr>
<td>100 mg</td>
<td>100 mg</td>
</tr>
</tbody>
</table>

The recommended total daily dose of Trokendi XR® as treatment for prevention of migraine headaches is 100 mg once daily.

**Dose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used.**

Monitoring for therapeutic blood levels

It is not necessary to monitor topiramate plasma concentrations to optimize Trokendi XR therapy.

**Administration instructions**

Trokendi XR may be taken without regard to meals. Swallow capsule whole and intact. Do not sprinkle on food, chew, or crush.

**Contraindications**

Trokendi XR is contraindicated in patients with recent alcohol use (within 6 hours prior to and 6 hours after Trokendi XR use), and also in patients with metabolic acidosis who are taking concomitant metformin.

**Trokendi XR® delivers a once-daily migraine prevention treatment that offers seamless conversion**

**CONVERSION**

Same total daily dose, same-day2

<table>
<thead>
<tr>
<th>Total daily dose</th>
<th>Twice-daily Topamax</th>
<th>Once-daily Trokendi XR</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 mg</td>
<td>25 mg/day</td>
<td>25 mg/day</td>
</tr>
<tr>
<td>50 mg</td>
<td>50 mg/day</td>
<td>50 mg/day</td>
</tr>
<tr>
<td>100 mg</td>
<td>100 mg/day</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>200 mg</td>
<td>200 mg/day</td>
<td>200 mg/day</td>
</tr>
</tbody>
</table>

**INDICATION**

Trokendi XR (topiramate) extended-release capsules are indicated for prophylaxis of migraine headaches in adults and adolescents 12 years and older.

The usefulness of Trokendi XR in the acute treatment of migraine headaches has not been studied.

Please refer to the full Prescribing Information and Important Safety Information enclosed for complete information on Trokendi XR, or visit www.TrokendiXR.com.
**WARNINGS & PRECAUTIONS**

**IMPORTANT SAFETY INFORMATION**

**INDICATION**

Trokendi XR® is a CNS depressant. Concomitant administration of Trokendi XR with other CNS depressant drugs can result in significant CNS depression. Patients should be watched carefully when Trokendi XR is co-administered with other CNS depressant drugs.

**DOSEING GUIDELINES & CONSIDERATIONS**

**ADVERSE REACTIONS**

Trokendi XR has not been studied in a randomized, placebo-controlled, phase 3 clinical study. However, it is expected that Trokendi XR will produce a similar adverse reaction profile as that of immediate-release topiramate. See the ADVERSE REACTIONS section of the Trokendi XR full prescribing information for further adverse reaction rates from clinical trials conducted under widely varying conditions.

In migraine prophylaxis trials of 10 mg immediate-release topiramate, the most common adverse reactions in adults that were higher than placebo were paresthesia (51 v. 6%, 100 mg/day v. placebo), anorexia (15 v. 6%), and weight loss (15 v. 5%). In a 12-week, 15 mg/day immediate-release topiramate trial in children that was not placebo-controlled, the most common adverse reactions were headache (11 v. 6%), somnolence (8 v. 6%), and anorexia (7 v. 6%).

**REFERENCES**


*References and Citations. Other information in the product labeling (e.g. section 10) are subject to a private license on any electronic or print version of this labeling that patient has no access to. Other material not subject to a patient’s license on any electronic or print version of this labeling that patient has no access to. Other materials and information are intended for healthcare professionals and can be obtained through various electronic and print sources.*

**MDM**

**Important Safety Information**

**Trokendi XR** (topiramate) extended-release capsules are indicated for prophylaxis of migraine headaches in adults and adolescents 12 years and older. The use of Trokendi XR in the acute treatment of migraine headaches has not been studied.

**SPECIAL CARE INDICATIONS**

Trokendi XR is contraindicated in patients with recent alcohol use (within 6 hours prior to and 6 hours after Trokendi XR use), and also in patients with metabolic acidosis who are taking concomitant metformin.

**INDICATION**

Topiramate with or without concomitant valproic acid (VPA) has been associated with a syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in adults and pediatric patients treated with topiramate. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior.

**INDICATION**

Topiramate for adults for prophylaxis of migraine was higher than in the epilepsy controlled trials, suggesting that Trokendi XR would produce a similar adverse reaction profile as that of immediate-release topiramate. See the ADVERSE REACTIONS section of the Trokendi XR full prescribing information for further adverse reaction rates from clinical trials conducted under widely varying conditions.

In migraine prophylaxis trials of 10 mg immediate-release topiramate, the most common adverse reactions in adults that were higher than placebo were paresthesia (51 v. 6%, 100 mg/day v. placebo), anorexia (15 v. 6%), and weight loss (15 v. 5%). In a 12-week, 15 mg/day immediate-release topiramate trial in children that was not placebo-controlled, the most common adverse reactions were headache (11 v. 6%), somnolence (8 v. 6%), and anorexia (7 v. 6%).